A phase-IIa, double-blind, randomized, controlled study on the tolerability and early efficacy of hLF1-11 [human lactoferrin 1-11 peptide] in hospitalized patients with bacteremia due to staphylococcus epidermidis

Trial Profile

A phase-IIa, double-blind, randomized, controlled study on the tolerability and early efficacy of hLF1-11 [human lactoferrin 1-11 peptide] in hospitalized patients with bacteremia due to staphylococcus epidermidis

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2014

At a glance

  • Drugs Lactoferrin 1-11 (Primary)
  • Indications Bacteraemia; Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LIST
  • Sponsors AM-Pharma
  • Most Recent Events

    • 13 Jan 2010 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Status changed from not yet recruiting to suspended.
    • 23 Apr 2008 The expected completion date for this trial is now 1 Dec 2008, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top